Ipilimumab Approved by FDA for Pediatric Melanoma

Ipilimumab (Yervoy) has been approved by the FDA for the treatment of patients aged greater than or equal to 12 years with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.

Read the full story

Posted in Melanoma In The News, FDA

FDA grants orphan drug designation to pIL-12 for unresectable melanoma

The FDA granted orphan drug designation to tavokinogene telsaplasmid for the treatment of unresectable metastatic melanoma, according to the agent’s manufacturer.

Read the full story

Posted in Melanoma In The News, FDA

FDA fast tracks ocular melanoma treatment

A new class of treatment that can selectively destroy cancer cells using a light-activated viral nanoparticle has received FDA fast track designation for the treatment of ocular melanoma.

Read the full story

Posted in Melanoma In The News, FDA, Information

FDA grants fast track designation to ImmunoPulse IL-12 for melanoma

The FDA granted fast track designation to ImmunoPulse IL-12 for the treatment of metastatic melanoma that progressed during therapy with pembrolizumab or nivolumab.

Read the full story

Posted in Melanoma In The News, FDA

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories